Reaction profile

The FDA adverse-event record for pr-esophagus, lesion(s)

Name: PR-ESOPHAGUS, LESION(S) - FDA Animal Adverse Reaction
Creator: PlainBreed
License: https://open.fda.gov/license/

13 FDA reports name pr-esophagus, lesion(s), a lower-volume reaction in the CVM extract (VeDDRA 99611). Plate stamps and neighbourhood peers follow.

#2368 of 2,481
by report volume (all reactions): 13
reports citing this reaction: 84.6%
death-coded share: Dog
most-affected species

Compiled by PlainBreed

Verify with FDA CVM →

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. PR-ESOPHAGUS, LESION(S) has 13 reports now versus 13 in that prior snapshot: 0 the same number of (0.0%).

Report change: +0
Death-coded reports: +0
Death-coded share: −0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to PR-ESOPHAGUS, LESION(S) changes

FDA AER · VeDDRA plate

Code 99611 VOL-TRACE

VOL-TRACE · DEATH-HOT · BOTTOM-DECILE · PHOTO-FINISH · SPECIES-DOG · DRUG-LEAD · DESK-WIDE · BOOK-FULL

VOL-TRACE 13 reports
DEATH-HOT 84.6%
BOTTOM-DECILE #2368/2481
PHOTO-FINISH Abnormal digital pulse
SPECIES-DOG Dog · 5
DRUG-LEAD Carprofen · 2
DESK-WIDE 12 breeds
BOOK-FULL 8/8 fields

Nearest volume peer: Abnormal digital pulse (±0 reports)

Upper-third death-coded share drives the outcome stamps on this plate; volume band, corpus rank, and co-report peers follow. Not a clinical diagnosis.

Lower-volume neighbourhood around PR-ESOPHAGUS, LESION

Lower-third volume poles plus nearest peers, not a full reaction corpus board reprint.

FDA AER report volume · neighbourhood around PR-ESOPHAGUS, LESION(S)

PR-ESOPHAGUS, LESION(S): high death-coded share in the FDA AER plate

Signature read: PR-ESOPHAGUS, LESION(S)'s 84.6% death-coded share is among the highest in the openFDA reaction corpus. Report volume is lower-third scale: 13 named reports in the openFDA extract. Death-coded share is upper-third: 11 of 13 reports (84.6% of named reports). Nearest volume peer: Abnormal digital pulse (±0 reports). Lead species Dog (5). Lead co-reported drug Carprofen (2).

Read these counts as reporting volume, not risk: per our methodology, A high death-coded share in FDA filings does not prove causation; co-reporting is voluntary temporal association only. Browse the full reactions index or the about page for how PlainBreed frames FDA CVM extracts.

Species Most Affected

Dog 5

Cattle 3

Cat 3

Guinea Pig 1

Horse 1

Breeds Most Affected

Domestic (unspecified) 2

Unknown 1

Deutsche Dogge, Great Dane 1

Cattle (unknown) 1

Collie - Border 1

Charolais 1

Thoroughbred 1

Domestic Mediumhair 1

Siberian Husky 1

Jersey 1

Associated Drugs

Carprofen 2

Maropitant Citrate 2

Fluralaner Chew Tablets 2

Selamectin 1

Deracoxib 1

Albendazole 1

Cefovecin Sodium 1

Amoxicillin 1

Famotidine 1

Anesthetic 1

Cephalexin 1

Amoxicillin, Clavulanate 1

Ivermectin 1

Ceftiofur Crystalline Free Acid 1

Clindamycin Hydrochloride 1

Dexmedetomidine Hydrochloride 1

Cefovecin 1

Pegbovigrastim 1

Calcium 1

Ivermectin + Pyrantel As Pamoate Salt 1

What to do with this reaction

Read how death-coded share differs from a mortality rate before drawing conclusions. Understanding adverse events
Browse the full reaction directory to compare report counts across reaction types. All reactions

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for PR-ESOPHAGUS, LESION(S) (#2368 of 2,481 by report volume); death-coded 84.6%. PlainBreed reaction plate · death-coded share stamp 84.6% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →